Skip to main content

Table 3 Evidence synthesis

From: Medication adherence influencing factors—an (updated) overview of systematic reviews

Factor

Relationship

Indication/therapy

Effect direction

Evidence for effect

Social and economic

Education

Parkinson disease

O

Chronic pain

?

O

Hepatitis C

O

HIV

Oral anti-cancer agents

O

?

O

Cardiovascular conditions

+

O

?

O

Employed

Hepatitis C

O

Inflammatory arthritis

?

O

HIV

+

Cardiovascular conditions

O

O

?

O

Ethnic status

Hepatitis C

?

O

Others > African American

O

Inflammatory arthritis

White > others

+

HIV

White > Black

+

Oral anti-cancer agents

White > Black

O

White > Asian

White > Hispanic

White > non-White

O

African American > others

O

Non-White > others

O

Cardiovascular conditions

White > others

++

Non-Asian > Asian

O

Major ethnic groups > ethnic minorities

+

Financial status/income

Parkinson disease

O

Hepatitis C

O

Chronic conditions

+

Oral anti-cancer agents

+

Cardiovascular conditions

O

?

O

Socioeconomic status

Inflammatory arthritis

O

Oral anti-cancer agents

?

O

O

Cardiovascular conditions

+

Married/not living alone

Parkinson disease

O

Inflammatory arthritis

O

Chronic conditions

?

O

HIV

O

Oral anti-cancer agents

O

O

?

Cardiovascular conditions

O

?

O

Social support

Inflammatory arthritis

O

Oral anti-cancer agents

?

O

O

Cardiovascular conditions

O

O

Therapy related

Duration of therapy

Oral anti-cancer agents

?

O

1 year > 3 or 5 years

More than 2 years > 0–2 years

Frequency of intake

Parkinson disease

O

Inflammatory arthritis

?

O

Cardiovascular conditions

?

O

Number of pills taken per day

Cardiovascular conditions

?

O

Number of tablets

Oral anti-cancer agents

?

O

2 > 1

O

Different medications

Parkinson disease

O

Chronic pain

O

O

Inflammatory arthritis

O

Oral anti-cancer agents

O

O

?

O

Cardiovascular conditions

+

?

O

Taking medication at meals

Oral anti-cancer agents

O

Disease related

Duration of disease

Chronic pain

?

O

Hepatitis C

O

Inflammatory arthritis

Oral anti-cancer agents

O

?

Cardiovascular conditions

O

O

?

Patient related

Age (years)

Parkinson disease

+

Chronic pain

O

Hepatitis C

?

O

Inflammatory arthritis

O

55–64 > others

O

Chronic conditions

O

O

65 and older > younger than 65

O

HIV

18–40 < age more than 41

O

Age less than 45 vs. more than 45

+

Oral anti-cancer agents

Middle age > very old (≥ 75) > young (≤ 45)

+

Middle age (41–60) > others

O

Less than 45 < others

O

Less than 46 or more than 85 > others

O

 

O

?

O

 

O

Cardiovascular conditions

O

+

  

?

O

≤ 55 < others

O

≤ 55: NR

O

> 60 > others

O

35–56 > others

 
 

O

Comorbidity

Inflammatory arthritis

O

Oral anti-cancer agents

Charlson comorbidity index: ↑

O

 
 

O

Comorbidity (physical)

Hepatitis C

O

?

O

Chronic conditions

O

Cardiovascular conditions

O

O

O

Comorbidity (mental)

Parkinson disease

O

Hepatitis C

+

O

O

?

O

Chronic conditions

O

Cardiovascular conditions

+

O

?

O

Comorbidity (depression)

Oral anti-cancer agents

+

HIV

+

Cardiovascular conditions

++

Gender (female)

Chronic pain

O

Hepatitis C

O

O

?

O

Inflammatory arthritis

O

O

Chronic conditions

O

?

O

Oral anti-cancer agents

O

O

?

O

Cardiovascular conditions

+

?

O

O

Health care system related

Co-payments

Inflammatory arthritis

+

Chronic conditions

+

Not restricted

++

Oral anti-cancer agents

Less than US$10 > more than US$10

O

O

O

Cardiovascular conditions

+

No > yes

+

Yes > no

O

US$0 > US$1 to US$9

+

US$0 > US$10 to US$29

+

Medication costs

Inflammatory arthritis

O

Oral anti-cancer agents

O

Health insurance

Chronic conditions

O

Cardiovascular conditions

O

?

O

  1. Effect direction. positive effect on adherence, negative effect on adherence, inconsistent effect direction, ? effect direction not or unclearly reported, ++ robust evidence for an impact, + some evidence for an impact, − probably no impact, O uncertain impact